Navigation Links
Generation of Fully Human Monoclonal Antibodies Neutralizing Influenza Virus - Use of SPYMEG as a novel human lymphocyte fusion partner

NAGOYA, Japan, Jan. 26 /PRNewswire/ -- Medical & Biological Laboratories Co., Ltd. (MBL), with the collaboration of Osaka University, has successfully generated several fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza virus by utilizing blood samples from volunteers who were inoculated with influenza vaccine.

Professor Kazuyoshi Ikuta, Ph. D., at the Department of Virology, Research Institute for Microbial Diseases, Osaka University, has confirmed through in vitro experiments that the fully generated human antibodies can neutralize H3N2 influenza virus strains. Professor Ikuta is now evaluating the preventative and therapeutic effects in an infected mouse model. After completing in vivo experiments in infected animal models with the neutralizing antibodies, MBL plans to commence a collaborative clinical development program with a pharmaceutical company. These neutralizing human IgG antibodies against the influenza virus are expected to be effective in severe infections. In combination with anti-viral drugs these antibodies will have greater success than anti-viral drugs alone.

The therapeutic antibodies were generated by using a special cell line, called SPYMEG. This novel cell line is a human lymphocyte fusion partner, it was co-developed by associate professor Naomasa Yamamoto, Ph. D., of Ohu University and MBL. SPYMEG is the cell line established by the cell fusion of MEG-01 with a murine myeloma cell line. Hybridoma cells of human origin are known to be prone to chromosome deletions. The SPYMEG cell line overcomes that problem, resulting in a higher reliability of cell fusion. Utilization of SPYMEG is a simpler and easier way to generate therapeutic monoclonal antibodies than chimerization, or humanization of mouse monoclonal antibodies generated from immunized mice.

At present, MBL is conducting collaborative research to generate neutralizing monoclonal antibodies against swine-origin influenza A (H1N1). MBL is preparing to collaborate with more institutions regarding other infectious viruses.

The fully human monoclonal antibodies against pandemic A (H1N1 and H3N2) type influenza viruses were generated by the utilization of SPYMEG. The antibodies, originated from the blood of a convalescent volunteer recovering from influenza infection or vaccination, are expected to be effective and very safe.

Additionally, the simple principle and wide range of applications of this method may lead to the generation of therapeutic and prophylactic drugs to various infections such as avian influenza A (H5N1).

About MBL

MBL was first established as a Japanese antibody manufacturer in 1969. Since then, the company has been involved in the research, development, manufacture and sale of diagnostic and research reagents.

In the research reagent sector, MBL has been engaged in the worldwide sales of more than 8,000 antibodies that are developed in-house or marketed by foreign and domestic alliance partners. MBL also provides the contract manufacturing of custom-made monoclonal and polyclonal antibodies. MBL has also extended its offering to provide identification kits for mRNA and contract analysis of carbohydrate structure.

In the diagnostic reagent sector, MBL has developed in vitro diagnostic reagents for autoimmune diseases, cancers and aberrant metabolite disorders. As a leader in autoimmune disease diagnostics, MBL's diagnostic products have aided detection of diseases, especially those with poor therapeutic options. MBL also provides an advanced cytopreparation system for the sampling and diagnosis of cervical cancer.

MBL is proud to be an antibody manufacturer with commitment to drug discovery focusing on therapeutic monoclonal antibodies.

About MBL International

MBL International, a subsidiary of MBL, is a leading biotechnology company focused on research, development, production and distribution of research reagents for the life science marketplace worldwide.

MBL International introduces a broad range of innovative antibodies and antibody-related products in the areas of immunology, cancer, autophagy, apoptosis, allergy, fluorescence and other research.  Our products include fluorescent protein vectors, kinase assay ELISA kits, monoclonal antibodies, recombinant proteins and the industry's largest selection of G-Protein Coupled Receptor antibodies.  MBL International also manufactures and distributes diagnostic ELISA and IF kits in the areas of autoimmune disease, virology and infectious diseases.

In 2008, MBL International increased the company's offering of diagnostic products that are used to test for and diagnose severe skin diseases, viral infections and many additional autoimmune diseases. MBL International is your immune system research provider.

SOURCE MBL International Corporation



SOURCE MBL International Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Osteotech Submits 510(k) Application to FDA for Clearance of its Duratech(TM) BioRegeneration Matrix
2. Indiana Industry, University and Community Leaders Capitalize on Next Generation of States Life Sciences Growth
3. DONG Energy and Inbicon Inaugurate One of the Worlds Largest Demo Plants for 2nd Generation Biofuel
4. DuPont, Dow AgroSciences Agree to Cross License Next-Generation Soybean Herbicide Tolerant Traits
5. UD wins $4.4 million to develop next-generation magnets
6. Pieris Reports Preclinical Development Progress of its Next Generation VEGF Antagonist
7. Parameter Generation and Control Launches New Catalog "Pharmaceutical Stability Solutions"
8. Boston Biotech R&D Conference to Showcase Next-Generation Newsmakers and Massachusetts as Leader in Biotech Discovery
9. Ontario Institute for Cancer Research Validates NEBNext(TM) DNA Sample Preparation Reagents from New England Biolabs for use in Next Generation Sequencing
10. Boston Scientific Announces Release of Next-Generation iLab(R) System Software
11. Boston Scientific Completes Enrollment in Pivotal Workhorse Trial for Next-Generation Everolimus Stent
Post Your Comments:
(Date:6/27/2016)... 27, 2016  Global demand for enzymes is ... 2020 to $7.2 billion.  This market includes enzymes ... products, biofuel production, animal feed, and other markets) ... biocatalysts). Food and beverages will remain the largest ... consumption of products containing enzymes in developing regions.  ...
(Date:6/27/2016)... ... June 27, 2016 , ... Newly created ... and solutions to the healthcare market. The company's primary focus is on new ... and marketing strategies that are necessary to help companies efficiently bring their products ...
(Date:6/24/2016)... Epic Sciences unveiled a liquid biopsy ... PARP inhibitors by targeting homologous recombination deficiency (HRD) ... test has already been incorporated into numerous clinical ... Over 230 clinical trials are investigating ... PARP, ATM, ATR, DNA-PK and WEE-1. Drugs targeting ...
(Date:6/23/2016)... CAMBRIDGE, Mass. , June 23, 2016 /PRNewswire/ ... the development of novel compounds designed to target ... compound, napabucasin, has been granted Orphan Drug Designation ... in the treatment of gastric cancer, including gastroesophageal ... cancer stemness inhibitor designed to inhibit cancer stemness ...
Breaking Biology Technology:
(Date:6/22/2016)... 22, 2016  The American College of Medical Genetics and ... Magazine as one of the fastest-growing trade shows during ... the Bellagio in Las Vegas . ... of growth in each of the following categories: net square ... number of attendees. The 2015 ACMG Annual Meeting was ranked ...
(Date:6/22/2016)... 2016 On Monday, the Department of Homeland ... share solutions for the Biometric Exit Program. The Request ... Protection (CBP), explains that CBP intends to add biometrics ... the United States , in order to deter ... Logo - ...
(Date:6/20/2016)... 20, 2016 Securus Technologies, a leading ... for public safety, investigation, corrections and monitoring announced ... it has secured the final acceptance by all ... Managed Access Systems (MAS) installed. Furthermore, Securus will ... be installed by October, 2016. MAS distinguishes between ...
Breaking Biology News(10 mins):